Heparan sulphate with no affinity for antithrombin III and the control of haemostasis
- PMID: 2973992
- DOI: 10.1016/0014-5793(88)81020-2
Heparan sulphate with no affinity for antithrombin III and the control of haemostasis
Abstract
Heparan sulphate with no affinity for antithrombin III (ATIII) was observed to cause acceleration of the factor Xa:ATIII interaction by 1100-fold (k2, 7 X 10(7) M-1.min-1) and the prothrombinase:ATIII interaction by 2900-fold (k2, 2.5 X 10(7) M-1.min-1). Although high-affinity heparan sulphate catalyzed higher acceleration and at lower concentration, in natural mixtures of the two forms the activity of the no affinity form predominated. Heparan sulphate had no significant effect on the thrombin:ATIII interaction but inhibited its potentiation by heparin (Kd 0.3 microM). From the estimated concentration of heparan sulphate on the endothelial cell surface it is proposed that the non-thrombogenic property of blood vessels is due to the acceleration of the factor Xa or prothrombinase:ATIII interaction by the greater mass of surface-bound heparan sulphate rather than by the much smaller proportion of heparin-like molecules (with high affinity for antithrombin III) which may be present.
Similar articles
-
Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.Biochem J. 1989 Sep 1;262(2):651-8. doi: 10.1042/bj2620651. Biochem J. 1989. PMID: 2529852 Free PMC article.
-
Comparative effect of heparin and heparan sulphate on two abnormal antithrombin III type 3 variants.Br J Haematol. 1987 Jun;66(2):213-7. doi: 10.1111/j.1365-2141.1987.tb01301.x. Br J Haematol. 1987. PMID: 2955807
-
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.Blood. 1984 Sep;64(3):742-7. Blood. 1984. PMID: 6235872
-
Mechanisms for the anticoagulant effect of heparin and related polysaccharides.Nouv Rev Fr Hematol (1978). 1988;30(3):155-60. Nouv Rev Fr Hematol (1978). 1988. PMID: 2971155 Review.
-
Orgaran (Org 10172): its pharmacological profile in experimental models.Haemostasis. 1992;22(2):58-65. doi: 10.1159/000216296. Haemostasis. 1992. PMID: 1379965 Review.
Cited by
-
Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.Biochem J. 1989 Sep 1;262(2):651-8. doi: 10.1042/bj2620651. Biochem J. 1989. PMID: 2529852 Free PMC article.
-
Heparan sulfate 3-O-sulfation: a rare modification in search of a function.Matrix Biol. 2014 Apr;35:60-72. doi: 10.1016/j.matbio.2013.12.001. Epub 2013 Dec 19. Matrix Biol. 2014. PMID: 24361527 Free PMC article. Review.
-
New Functional Tools for Antithrombogenic Activity Assessment of Live Surface Glycocalyx.Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1847-53. doi: 10.1161/ATVBAHA.116.308023. Epub 2016 Jul 7. Arterioscler Thromb Vasc Biol. 2016. PMID: 27386939 Free PMC article.
-
Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor.J Biol Chem. 2011 Mar 18;286(11):8740-51. doi: 10.1074/jbc.M110.188375. Epub 2011 Jan 10. J Biol Chem. 2011. PMID: 21220417 Free PMC article.
-
Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.Blood. 2008 Apr 15;111(8):4118-25. doi: 10.1182/blood-2007-12-127928. Epub 2008 Feb 15. Blood. 2008. PMID: 18281504 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous